Skip to content

US · PLSM · MEDICAL - DEVICES

Pulsenmore Ltd. Ordinary Shares (PLSM) intrinsic value and stock valuation

$1.29as of 2026-11-21 · Mkt cap 23.02M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Pulsenmore Ltd. Ordinary Shares DCF and intrinsic value

InvestorsCraft values PLSM with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from PLSM’s statements →

Pulsenmore Ltd. Ordinary Shares Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Omer, HD 8496500 pulsenmore.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$40M
20192025
Net income
-$-15.85M
20192025
Free cash flow
-$-33.01M
20192025
Total equity
$83.1M+95.8% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$40M$9.64M$6.14M$10.6M$1.58M
Operating income-$-12.16M-$-42.12M-$-55.11M-$-45.25M-$-21.92M
Net income-$-15.85M-$-36.65M-$-58.07M-$-21.66M-$-25.61M
EPSd-$-2.47M-$-5.73M-$-9.07M-$-3.59M-$-4.99M
Operating cash flow-$-32.88M-$-33.71M-$-42.45M-$-24.51M-$-26.01M
Capital expenditure-$-140K-$-510K-$-3.89M-$-4.41M-$-770K
Free cash flow-$-33.01M-$-34.22M-$-46.34M-$-28.92M-$-26.79M
Total assets$101.9M$141.5M$178.4M$231.5M$167M
Total debt$1.56M$3.23M$5.69M$6.92M$1.02M
Net debt-$-20.04M-$-37.98M-$-18.12M-$-8.27M-$-111.9M
Total equity$83.1M$96.7M$132.2M$187.5M$153.6M
Cash and short-term investments$69.1M$103.9M$140.7M$179.6M$153.4M
Income statement
20252024202320222021
Revenue$40M$9.64M$6.14M$10.6M$1.58M
Cost of revenue$6.34M$7.57M$6.1M$6.72M$1.37M
Gross profit$33.7M$2.07M$40K$3.87M$210K
Research and development expenses$17.4M$18.9M$30.1M$28.3M$10.6M
Selling, general and administrative expenses$10.6M$34M$32.6M$29.3M$16.3M
Other expenses$17.9M-$-8.68M-$-7.53M-$-8.47M-$-4.76M
Operating expenses$45.9M$44.2M$55.2M$49.1M$22.1M
Cost and expenses$52.2M$51.8M$61.3M$55.9M$23.5M
Interest income$3.54M$5.31M$6.79M$3.03M$80K
Interest expense$320K$540K$610K$340K$290K
Depreciation and amortization$2.8M$2.85M$2.38M$1.27M$560K
Ebitda-$-12.73M-$-33.32M-$-54.95M-$-20.05M-$-24.76M
Operating income-$-12.16M-$-42.12M-$-55.11M-$-45.25M-$-21.92M
Total other income/expenses, net-$-3.69M$5.41M-$-2.83M$23.6M-$-3.68M
Income before tax-$-15.85M-$-36.71M-$-57.94M-$-21.66M-$-25.61M
Income tax expense$0.00-$-60K$130K$0.00$0.00
Net income-$-15.85M-$-36.65M-$-58.07M-$-21.66M-$-25.61M
Weighted average shares outstanding$6.43M$6.4M$6.4M$6.03M$5.13M
Weighted average diluted shares outstanding$6.43M$6.4M$6.4M$6.03M$5.13M
Balance sheet
20252024202320222021
Cash and short-term investments$69.1M$103.9M$140.7M$179.6M$153.4M
Net receivables$4.89M$4.6M$2.08M$11.1M$5.32M
Inventory$6.59M$23.3M$23.7M$16.6M$6.55M
Total current assets$81.4M$132.1M$166.5M$207.3M$165.2M
Property, plant and equipment, net$7.11M$9.4M$11.9M$8.93M$1.8M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$15.3M$0.00
Total non-current assets$20.4M$9.4M$11.9M$24.2M$1.8M
Total assets$101.9M$141.5M$178.4M$231.5M$167M
Accounts payable$1.98M$2.35M$4.88M$5.74M$830K
Short-term debt$2.04M$1M$920K$850K$550K
Deferred revenue$940K$5.12M$5.09M$5.04M$2.29M
Total current liabilities$10.3M$14.2M$14.3M$15.2M$6.71M
Long-term debt$540K$2.23M$4.77M$6.08M$460K
Deferred revenue, non-current$0.00$22.9M$22.7M$22.3M$0.00
Total non-current liabilities$8.43M$24.1M$26.6M$26.5M$1.06M
Capital lease obligations$1.56M$1.12M$2.39M$3.04M$230K
Total liabilities$18.8M$38.4M$47.7M$48.8M$7.76M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-183.14M-$-166.91M-$-129.44M-$-70.51M-$-49.83M
Accumulated other comprehensive income (loss)$10.1M$10.9M$10.2M$7.08M$2.52M
Total equity$83.1M$96.7M$132.2M$187.5M$153.6M
Total investments$47.5M$62.7M$116.9M$179.6M$40.5M
Total debt$1.56M$3.23M$5.69M$6.92M$1.02M
Net debt-$-20.04M-$-37.98M-$-18.12M-$-8.27M-$-111.9M
Cash flow statement
20252024202320222021
Net income-$-15.85M-$-36.65M-$-58.07M-$-21.66M-$-25.61M
Depreciation and amortization$2.8M$2.85M$2.38M$1.27M$560K
Stock-based compensation$670K$0.00$0.00$0.00$0.00
Change in working capital-$-24.05M-$-3.53M$390K$9.47M-$-6.81M
Accounts receivable-$-390K-$-2.81M$10.3M-$-6.49M-$-7.12M
Inventory$3.16M$600K-$-9.36M-$-9.57M-$-2.61M
Accounts payable-$-380K-$-2.56M-$-930K$4.93M$160K
Net cash provided by operating activities-$-32.88M-$-33.71M-$-42.45M-$-24.51M-$-26.01M
Investments in property, plant and equipment-$-140K-$-510K-$-3.89M-$-4.41M-$-770K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$13.9M$50.8M$49.4M-$-297.7M-$-41.22M
Common stock issued$30K$0.00$0.00$50.1M$174.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$0.00-$-1.56M-$-1.13M$49.9M$178.3M
Net change in cash-$-19.57M$17.2M$7.94M-$-110.16M$107M
Cash at end of period$21.6M$41.2M$23.8M$15.2M$112.9M
Operating cash flow-$-32.88M-$-33.71M-$-42.45M-$-24.51M-$-26.01M
Capital expenditure-$-140K-$-510K-$-3.89M-$-4.41M-$-770K
Free cash flow-$-33.01M-$-34.22M-$-46.34M-$-28.92M-$-26.79M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Pulsenmore Ltd. Ordinary Shares

        Pulsenmore Ltd. specializes in delivering self-scanning ultrasound technology for distant medical diagnosis and health screening throughout Israel and Europe. Its primary offering is the Pulsenmore at-home ultrasound system, which consists of a portable ultrasound unit that attaches to a patient's smartphone. An accompanying mobile application then securely uploads diagnostic images to the cloud for review. Furthermore, a specialized clinician dashboard enables medical professionals to examine stored video recordings or provide real-time guidance during a scan. Founded in 2014, the company is headquartered in Omer, Israel.

        CEO
        Elazar Sonnenschein
        Employees
        63
        Beta
        0.38

        Explore

        Frequently asked questions

        What is the intrinsic value of Pulsenmore Ltd. Ordinary Shares (PLSM)?

        Pulsenmore Ltd. Ordinary Shares (PLSM) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PLSM undervalued?

        PLSM trades at a price of $1.29 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.